| T2-hyperintense leiomyoma | High-grade ESS | Low-grade ESS |
---|---|---|---|
n | 16 | 11 | 9 |
Age (year) | |||
 Median (range) | 43 (30–49) | 64 (45–78) | 42 (29–55) |
Menopausal status | |||
 Premenopausal | 16 (100.0) | 1 (9.1) | 8 (88.9) |
 Postmenopausal | 0 (0.0) | 10 (90.9) | 1 (11.1) |
FIGO staging | |||
 I | N/A | 5 (45.5) | 8 (88.9) |
 II | N/A | 0 (0.0) | 0 (0.0) |
 III | N/A | 4 (36.4) | 1 (11.1) |
 IV | N/A | 2 (18.2) | 0 (0.0) |
Treatment | |||
 Surgery alone | 16 (100.0) | 3 (27.3) | 5 (55.6) |
 Surgery with adjuvant treatment | N/A | 7 (63.6) | 4 (44.4) |
 CCRT alone | N/A | 1 (9.1) | 0 (0.0) |